Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Patients should report side effects, concerns, or health changes
LIPO-C, however, has a broader, more foundational role: Liver Health Studies: It's a go-to for research involving non-alcoholic fatty liver disease (NAFLD) or general liver detoxification pathways
Critically, AOD-9604 did not produce the metabolic side effects associated with full-length growth hormone, including no insulin resistance or glucose intolerance, no elevation of IGF-1 levels, no fluid retention or joint pain, and no cardiovascular parameter changes
PlexusDx connects patients with licensed providers who may prescribe compounded GLP-1 medications from 503A compounding pharmacies